Wang Daoxi,Li Lang,Jiang Jun,et al.Research advances on etiology and treatment of pediatric osteoporosis[J].Journal of Clinical Pediatric Surgery,2023,22(07):689-693.[doi:10.3760/cma.j.cn101785-202303050-016]
儿童骨质疏松病因及治疗研究进展
- Title:
- Research advances on etiology and treatment of pediatric osteoporosis
- Keywords:
- Osteoporosis; Surgical Procedures; Operative; Child
- 摘要:
- 骨质疏松症会影响儿童和青少年的骨骼发育，是导致儿童严重残疾、生活质量降低的常见原因之一。骨质疏松症的病因复杂，分为继发性骨质疏松症和原发性骨质疏松症，其中继发性骨质疏松症更常见，病因包括长期使用糖皮质激素、恶性肿瘤、脑瘫、肌营养不良、系统性红斑狼疮等；原发性骨质疏松症相对罕见，包括成骨不全症、特发性青少年骨质疏松症、高胱氨酸尿症、马凡氏综合征等。骨质疏松症的特点是自发的频繁骨折，而发育中的儿童骨骼具有巨大的恢复和重塑潜力，因此早期发现并治疗骨质疏松症可以预防骨折，改善骨骼畸形，保留骨关节功能和儿童活动能力。本文就儿童骨质疏松病因及治疗的研究进展进行综述。
- Abstract:
- Affecting the skeletal development of children and adolescents, pediatric osteoporosis is one of the common causes leading to severe morbidity and reduced quality-of-life in children.Osteoporosis has a complex etiology and it may be divided into secondary and primary types.Secondary osteoporosis is more common with causes including long-term use of glucocorticoids, malignancies, cerebral palsy, muscular dystrophy and systemic lupus erythematosus.Primary osteoporosis is mostly rare, including osteogenesis imperfecta, idiopathic juvenile osteoporosis, cystinuria and Marfan’s syndrome.The characteristic of osteoporosis is frequent spontaneous fractures.In growing children, their skeletons have great potential for recovery and remodeling.Thus an early detection of osteoporosis may prevent fractures, improve bone deformities, preserve joint function and enhance mobility.The aim of this article is to review the research progress on the etiology and treatment of osteoporosis in children.
参考文献/References:
[1] El-Gazzar A, H?gler W.Mechanisms of bone fragility:from osteogenesis imperfecta to secondary osteoporosis[J].Int J Mol Sci, 2021, 22(2):625.DOI:10.3390/ijms22020625.
[2] Ciancia S, van Rijn RR, H?gler W, et al.Osteoporosis in children and adolescents:when to suspect and how to diagnose it[J].Eur J Pediatr, 2022, 181(7):2549-2561.DOI:10.1007/s00431-022-04455-2.
[3] Jang MJ, Shin C, Kim S, et al.Factors affecting bone mineral density in children and adolescents with secondary osteoporosis[J].Ann Pediatr Endocrinol Metab, 2023, 28(1):34-41.DOI:10.6065/apem.2244026.013.
[4] Li XF, Cui LK, Chen WH, et al.QiangGuYin modulates the OPG/RANKL/RANK pathway by increasing secretin levels during treatment of primary type I osteoporosis[J].Evid Based Complement Alternat Med, 2021, 2021:7114139.DOI:10.1155/2021/7114139.
[5] Matsumoto T, Endo I.RANKL as a target for the treatment of osteoporosis[J].J Bone Miner Metab, 2021, 39(1):91-105.DOI:10.1007/s00774-020-01153-7.
[6] Zou BH, Zheng JH, Deng WD, et al.Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca2+-NFATc1 and Cav-1 signaling pathways[J].Phytomedicine, 2021, 80:153377.DOI:10.1016/j.phymed.2020.153377.
[7] Bae S, Kim K, Kang K, et al.RANKL-responsive epigenetic me-chanism reprograms macrophages into bone-resorbing osteoclasts[J].Cell Mol Immunol, 2023, 20(1):94-109.DOI:10.1038/s41423-022-00959-x.
[8] Berkün O, F?nd?k Y, Akp?nar O, et al.Evaluation of RANK, RANKL and OPG levels in gingival crevicular fluid after surgically assisted rapid maxillary expansion[J].J Maxillofac Oral Surg, 2022, 21(2):487-492.DOI:10.1007/s12663-020-01481-1.
[9] Laine CM, Koltin D, Susic M, et al.Primary osteoporosis without features of OI in children and adolescents:clinical and genetic characteristics[J].Am J Med Genet A, 2012, 158A(6):1252-1261.DOI:10.1002/ajmg.a.35278.
[10] Laine CM, Laine T.Diagnosis of osteoporosis in children and adolescents[J].Eur Endocrinol, 2013, 9(2):141-144.DOI:10.17925/EE.2013.09.02.141.
[11] Engelke K, Lang T, Khosla S, et al.Clinical use of quantitative computed tomography (QCT) of the hip in the management of osteoporosis in adults:the 2015 ISCD official positions-part I[J].J Clin Densitom, 2015, 18(3):338-358.DOI:10.1016/j.jocd.2015.06.012.
[12] Bishop N, Arundel P, Clark E, et al.Fracture prediction and the definition of osteoporosis in children and adolescents:the ISCD 2013 Pediatric Official Positions[J].J Clin Densitom, 2014, 17(2):275-280.DOI:10.1016/j.jocd.2014.01.004.
[13] 郑荣飞, 熊丰.儿童骨质疏松症诊疗进展[J].中国实用儿科杂志, 2016, 31(3):227-232.DOI:10.7504/ek2016030617. Zheng RF, Xiong F.Advance in the diagnosis and treatment of osteoporosis in children[J].Chin J Pract Pediatr, 2016, 31(3):227-232.DOI:10.7504/ek2016030617.
[14] Bai ZM, Wang JG, Kang MM, et al.Effects of pamidronate disodium combined with calcium on BMD values and severity of pain in elderly patients with osteoporosis based on mobile terminal platform for Internet of things[J].Dis Markers, 2022, 2022:5069918.DOI:10.1155/2022/5069918.
[15] Golding PH.Dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) for diagnosis of osteoporosis-experimental data from artificial vertebrae confirms significant dependence on bone size[J].Bone Rep, 2022, 17:101607.DOI:10.1016/j.bonr.2022.101607.
[16] Agarwal S, Shane E, Lang T, et al.Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis:effect of teriparatide followed by denosumab[J].J Clin Endocrinol Metab, 2022, 107(7):e2690-e2701.DOI:10.1210/clinem/dgac232.
[17] Shevroja E, Cafarelli FP, Guglielmi G, et al.DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis[J].Endocrine, 2021, 74(1):20-28.DOI:10.1007/s12020-021-02806-x.
[18] Tan ZJ, Shek HT, Dong ZX, et al.Retrospective analyses of clinical features in 28 Chinese patients with type V osteogenesis imperfecta:new perspectives in an old issue[J].Osteoporos Int, 2023, 34(2):369-377.DOI:10.1007/s00198-022-06581-x.
[19] 王广, 林涨源, 卢邦宝, 等.儿童成骨不全症1例报告及文献综述[J].临床小儿外科杂志, 2023, 22(1):84-87.DOI:10.3760/cma.j.cn101785-202209010-016. Wang G, Lin ZY, Lu BB, et al.Osteogenesis imperfect:one case report with a literature review[J].J Clin Ped Sur, 2023, 22(1):84-87.DOI:10.3760/cma.j.cn101785-202209010-016.
[20] Dabas A, Malhotra R, Kumar R, et al.Idiopathic juvenile osteoporosis in a child:a four-year follow-up with review of literature[J].J Pediatr Endocrinol Metab, 2021, 34(11):1487-1490.DOI:10.1515/jpem-2021-0233.
[21] Janicka-Szczepaniak M, Orczyk K, Szymbor K, et al.Is it possible to predict a risk of osteoporosis in patients with juvenile idiopathic arthritis? A study of serum levels of bone turnover markers[J].Acta Biochim Pol, 2018, 65(2):297-302.DOI:10.18388/abp.2017_2561.
[22] 马燕华, 王覃, 李静, 等.特发性青少年骨质疏松症研究进展[J].中国骨质疏松杂志, 2022, 28(6):916-921.DOI:10.3969/j.issn.1006-7108.2022.06.024. Ma YH, Wang Q, Li J, et al.Research progress in idiopathic juvenile osteoporosis[J].Chin J Osteopor, 2022, 28(6):916-921.DOI:10.3969/j.issn.1006-7108.2022.06.024.
[23] 王立, 苏喆, 焦燕华.儿童骨质疏松症的诊治[J].中国实用儿科杂志, 2022, 37(8):595-600.DOI:10.19538/j.ek2022080607. Wang L, Su Z, Jiao YH.Diagnosis and treatment of osteoporosis in children[J].Chin J Pract Pediatr, 2022, 37(8):595-600.DOI:10.19538/j.ek2022080607.
[24] Saraff V, H?gler W.Endocrinology and adolescence:osteoporosis in children:diagnosis and management[J].Eur J Endocrinol, 2015, 173(6):R185-R197.DOI:10.1530/EJE-14-0865.
[25] Ward LM, Konji VN, Ma J.The management of osteoporosis in children[J].Osteoporos Int, 2016, 27(7):2147-2179.DOI:10.1007/s00198-016-3515-9.
[26] Formosa MM, Bergen DJM, Gregson CL, et al.A roadmap to gene discoveries and novel therapies in monogenic low and high bone mass disorders[J].Front Endocrinol (Lausanne), 2021, 12:709711.DOI:10.3389/fendo.2021.709711.
[27] Li C, Huang Q, Yang R, et al.Targeted next generation sequencing of nine osteoporosis-related genes in the Wnt signaling pathway among Chinese postmenopausal women[J].Endocrine, 2020, 68(3):669-678.DOI:10.1007/s12020-020-02248-x.
[28] Zhao Y, Yan JP, Zhu YM, et al.A novel prognostic 6-gene signature for osteoporosis[J].Front Endocrinol (Lausanne), 2022, 13:968397.DOI:10.3389/fendo.2022.968397.
[29] Hurley T, Zareen Z, Stewart P, et al.Bisphosphonate use in children with cerebral palsy[J].Cochrane Database Syst Rev, 2021, 7(7):CD012756.DOI:10.1002/14651858.CD012756.pub2.
[30] Yamasaki S, Kamezaki K, Ito Y, et al.Bisphosphonate use for glucocorticoid-induced osteoporosis in elderly patients with immune thrombocytopenia receiving prolonged steroid therapy:a single institute retrospective study[J].Hematol Rep, 2022, 14(3):276-285.DOI:10.3390/hematolrep14030039.
[31] Weng BF, Chen CH.Effects of bisphosphonate on osteocyte proliferation and bone formation in patients with diabetic osteoporosis[J].Comput Math Methods Med, 2022, 2022:2368564.DOI:10.1155/2022/2368564.
[32] Xu Q, Zhan P, Li XF, et al.Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment[J].J Cell Mol Med, 2021, 25(21):10126-10139.DOI:10.1111/jcmm.16949.
[33] Lee H, Lee S, Kim D, et al.Effect of dosing interval on compliance of osteoporosis patients on bisphosphonate therapy:observational study using nationwide insurance claims data[J].J Clin Med, 2021, 10(19):4350.DOI:10.3390/jcm10194350.
[34] Bandeira F, de Oliveira LB, Bilezikian JP.Long-term consequences of osteoporosis therapy with denosumab[J].Arch Endocrinol Metab, 2022, 66(5):717-723.DOI:10.20945/2359-3997000000560.
[35] Li PF, Wu XJ, Li Y, et al.Denosumab versus bisphosphonates for the prevention of the vertebral fractures in men with osteoporosis:an updated network meta-analysis[J].Clin Invest Med, 2022, 45(3):E14-E22.DOI:10.25011/cim.v45i3.38875.
[36] Kong SH.Denosumab, an effective osteoporosis treatment option for men[J].Korean J Intern Med, 2022, 37(5):947-948.DOI:10.3904/kjim.2022.261.
[37] Hoyer-Kuhn H, Rehberg M, Netzer C, et al.Individualized treatment with denosumab in children with osteogenesis imperfecta-follow up of a trial cohort[J].Orphanet J Rare Dis, 2019, 14(1):219.DOI:10.1186/s13023-019-1197-z.
[38] Kobayashi T, Nakamura Y, Suzuki T, et al.Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series[J].J Clin Med, 2018, 7(12):479.DOI:10.3390/jcm7120479.
[39] Uehara M, Nakamura Y, Takahashi J, et al.Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta[J].Tohoku J Exp Med, 2017, 242(2):115-120.DOI:10.1620/tjem.242.115.
[40] Hoyer-Kuhn H, Semler O, Schoenau E.Effect of denosumab on the growing skeleton in osteogenesis imperfecta[J].J Clin Endocrinol Metab, 2014, 99(11):3954-3955.DOI:10.1210/jc.2014-3072.
[41] Tamechika SY, Ohmura SI, Maeda S, et al.Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids[J].J Bone Miner Metab, 2023, 41(2):203-211.DOI:10.1007/s00774-022-01393-9.
[42] Lei MM, Tavares E, Buzgo E, et al.Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma[J].Leuk Lymphoma, 2022, 63(13):3249-3252.DOI:10.1080/10428194.2022.2115840.
[43] True HD, Ricks RG, Smith JA.Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal[J].Drug Ther Bull, 2023, 61(4):61-63.DOI:10.1136/dtb.2022.241203rep.
[44] Hoyer-Kuhn H, Franklin J, Allo G, et al.Safety and efficacy of denosumab in children with osteogenesis imperfect——a first prospective trial[J].J Musculoskelet Neuronal Interact, 2016, 16(1):24-32.
[45] Bacchetta J, Boutroy S, Vilayphiou N, et al.Teriparatide therapy and bone mineral accrual in children with idiopathic osteoporosis[J].J Bone Miner Res, 2020, 35(6):1087-1094.DOI:10.1002/jbmr.3982.
[46] Schweizer R, Martin DD, Haase M, et al.Similar effects of long-term exogenous growth hormone (GH) on bone and muscle parameters:a pQCT study of GH-deficient and small-for-gestational-age (SGA) children[J].Bone, 2007, 41(5):875-881.DOI:10.1016/j.bone.2007.06.028.
相似文献/References:
[1]杜朝峻,丁力,胡英超,等.手术治疗婴幼儿法洛四联症83例[J].临床小儿外科杂志,2010,9(06):413.
DU Chao jun,DING Li,HU Ying chao,et al.Surgical treatment of Tetralogy of Fallot in infancy: Experiences of 83 cases.[J].Journal of Clinical Pediatric Surgery,2010,9(07):413.
[2]李勇,尹强,周小渔,等.术中胆道造影在先天性胆总管囊肿手术中的应用[J].临床小儿外科杂志,2010,9(06):430.
LI Yong,YIN Qiang,ZHOU Xiao yu,et al.The clinic application experience on intraoperative cholangiography in pediatric surgery.[J].Journal of Clinical Pediatric Surgery,2010,9(07):430.
[3]许芝林,王强,李琰,等.乙状结肠冗长症的术式选择探讨[J].临床小儿外科杂志,2010,9(06):432.
XU Zhi lin,WANG Qiang,LI Yan,et al.Initiatory exploration of the standard of surgical treatment methods for Dolichosigmoid.[J].Journal of Clinical Pediatric Surgery,2010,9(07):432.
[4]常绘文,沈振亚.右腋下小切口在儿童心内手术中的应用[J].临床小儿外科杂志,2010,9(06):439.
[5]胡明,施诚仁,严志龙.脐环小切口治疗婴幼儿腹盆腔疾病的探讨[J].临床小儿外科杂志,2010,9(06):471.
[6]丁勇,魏华,孔燕,等.横裁包皮岛状皮瓣法在尿道下裂治疗中的应用[J].临床小儿外科杂志,2010,9(06):474.
[7]江峰赵阳孙莲萍金惠明马杰.婴幼儿阻塞性脑积水两种手术方式的疗效比较[J].临床小儿外科杂志,2011,10(01):0.
JIANG Feng,ZHAO Yang,SUN Liang ping,et al.Endoscopic third ventricul ostomy versus ventricul operitoneal shunt:clinical study of obstructive hydro cephalus in infants.[J].Journal of Clinical Pediatric Surgery,2011,10(07):0.
[8]王伟程少文彭磊林忠勤张伟陈庆玉寇冬权.弹性髓内钉在儿童肱骨骨折中的应用[J].临床小儿外科杂志,2011,10(01):0.
WANG Wei,CHENG Shaowen,PENG Lei,et al.Application of elastic intramedullary nailing in pediatric humeral fractures.[J].Journal of Clinical Pediatric Surgery,2011,10(07):0.
[9]景登攀张根领孙蔓丽.改良Snodgrass术治疗尿道下裂疗效观察[J].临床小儿外科杂志,2011,10(01):0.
[10]陈快 黄金狮 戴康临 陶俊峰 赖勇强 陶强. 腹腔镜与开腹Ladd手术治疗新生儿肠旋转不良效果比较[J].临床小儿外科杂志,2011,10(02):128.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):128.
[11]王广,林涨源,卢邦宝,等.儿童成骨不全症1例报告及文献综述[J].临床小儿外科杂志,2023,22(01):84.[doi:10.3760/cma.j.cn101785-202209010-016]
Wang Guang,Lin Zhangyuan,Lu Bangbao,et al.Osteogenesis imperfect: one case report with a literature review[J].Journal of Clinical Pediatric Surgery,2023,22(07):84.[doi:10.3760/cma.j.cn101785-202209010-016]
[12]周立军,谢华,陈方.输尿管不扩张的儿童完全性重复肾合并输尿管开口异位1例[J].临床小儿外科杂志,2023,22(07):686.[doi:10.3760/cma.j.cn101785-202204065-015]
Zhou Lijun,Xie Hua,Chen Fang.Diagnosis and treatment of ectopic ureter of complete duplex kidneys without ureteral dilation in children: one case report[J].Journal of Clinical Pediatric Surgery,2023,22(07):686.[doi:10.3760/cma.j.cn101785-202204065-015]
备注/Memo
收稿日期:2023-03-20。
基金项目:四川省自然科学基金（2022NSFSC1517）
通讯作者:刘利君,Email:ll1964@126.com